VIVOZON PHARMACEUTICAL CO., LTD.

As of March 31, 2026, VIVOZON PHARMACEUTICAL CO., LTD. carries a market capitalization of 194.03B, placing it among publicly traded companies globally. Its enterprise value stands at 214.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, VIVOZON PHARMACEUTICAL CO., LTD. has 60.16M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 3.09, and the price-to-book ratio stands at 1.99.

These figures are as of March 31, 2026. The EV/Sales ratio of 3.90 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 214.02B versus a market cap of 194.03B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, VIVOZON PHARMACEUTICAL CO., LTD. maintains a current ratio of 0.71, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 37.00, indicating elevated leverage, while an interest coverage ratio of -6.19 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, VIVOZON PHARMACEUTICAL CO., LTD. posted a negative return on equity (ROE) of -34.26, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.54, reflecting losses generated across the asset base. The company generates approximately 159.95M in revenue per employee across its workforce of 343.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.94 indicates how many times VIVOZON PHARMACEUTICAL CO., LTD. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, VIVOZON PHARMACEUTICAL CO., LTD.'s stock has declined approximately 39.05% over the past 52 weeks. The 50-day moving average sits at 2,993.80, while the 200-day moving average is 3,281.30.

Over the twelve months ended March 31, 2026, VIVOZON PHARMACEUTICAL CO., LTD. generated 54.86B in revenue and converted that into -34.21B in net income, yielding earnings per share of -649.35. EBITDA reached -15.07B, while operating income came in at -19.68B.

As of March 31, 2026, VIVOZON PHARMACEUTICAL CO., LTD. holds 16.17B in cash and equivalents against 36.16B in total debt, resulting in a net debt position of 20.88B. Total book value stands at 97.74B, with working capital of -16.67B providing operational flexibility.

VIVOZON PHARMACEUTICAL CO., LTD. produced -10.97B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -7.74B in capital expenditures, free cash flow totaled -18.71B - equivalent to -356.10 per share.

Over the twelve months ended March 31, 2026, VIVOZON PHARMACEUTICAL CO., LTD. posted a gross margin of 37.18, reflecting its pricing power and cost economics. The operating margin of -35.87 and net profit margin of -62.35 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -11.04: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -14.69, meaning VIVOZON PHARMACEUTICAL CO., LTD. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

VIVOZON PHARMACEUTICAL CO., LTD.'s most recent stock split took place on January 9, 2026 with a 883:939 split ratio.

As of March 31, 2026, VIVOZON PHARMACEUTICAL CO., LTD. has an Altman Z-Score of -1.44, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.